Home - Ferring Global
Ferring announces changes to Board of Directors and Executive Committee
Ferring and RedHill Biopharma enter strategic partnership for Rebyota® and Clenpiq®
Ferring successfully launches its fourth Swiss Franc Bond offering for CHF 250 million
Ferring and Gallup announce landmark global public attitudes study on fertility and family-building
Ferring today published its 2025 Annual Report and Sustainability Report
Family is at the heart of Ferring
At Ferring, we strive to unlock opportunities to deliver life-changing solutions to patients, bringing hope and joy to families across the world. We are committed to helping people become parents and to keeping mothers and babies healthy, from conception to birth. We are also passionate about making a difference to people’s health and quality of life through our work in gastroenterology and urology.
Believing in the power of research
Each of us at Ferring contribute to providing innovative solutions to help people live better lives. We devote significant research and development investment to new therapeutics, life cycle management and next generation healthcare solutions.
Join us
At Ferring Pharmaceuticals we highly value an attractive working environment that motivates our employees and stimulates the creative abilities and initiative of both individuals and teams. With more than 7,500 employees in over 50 countries, we are able to draw upon a large multicultural setting to enrich the work of our staff on all levels.
Helping people live better lives
Ferring Pharmaceuticals is a specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Ferring is a leader in reproductive medicine with a strong heritage in gastroenterology and urology and is at the forefront of innovation in uro-oncology gene therapy. Ferring has been developing treatments for mothers and babies for over 50 years.
News
Ferring Pharmaceuticals and Gallup announce landmark global public attitudes study on fertility and family-building
16 April 2026 - by celia
Ferring Global Fertility Monitor will gather data from a representative sample in 70 countries as a part of the Gallup World Poll Consultation to gather expert opinion on high impact questions begins this year…
For the first time, Ferring reports revenue of over €2.5 billion in 2025
10 March 2026 - by celia
Ferring’s total revenues for 2025 exceeded €2.5 billion, an increase of 10% from 2024, mainly driven by our flagship product Menopur®. Continued ramp-up in the US for Adstiladrin®, our novel gene-based therapy for bladder cancer, confirming its position as Ferring’s second major growth driver. Commitment to sustainability demonstrated by SBTi approval…
With two in five employees undergoing fertility treatment leaving their jobs or considering quitting, are companies doing enough?
26 November 2025 - by celia
An international survey from Ferring, Fertility Matters at Work and This Can Happen reveals a significant gap exists between employees and employers in recognising the experience of undergoing fertility treatment…